Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03450850 | Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma | completed | N/A | 1 | Daniela A. BotaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03681028 | Feasibility of Individualized Therapy for Recurrent Glioblastoma | completed | Phase 1 | 30 | Jennifer ClarkeOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07405047 | Fractionated Stereotactic Radiotherapy for Limited Small Volume Brain Metastases | completed | N/A | 33 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04822688 | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues | completed | — | 141 | Thomas Jefferson UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04173104 | PET and MRI Imaging of Brain Tumors Using [18F]PARPi | completed | Early Phase 1 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01022515 | Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma(PHEO) | completed | N/A | 60 | University Hospital, RouenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03048240 | INtraoperative photoDYnamic Therapy of GliOblastoma(INDYGO) | completed | N/A | 10 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03361033 | Components of Social Functioning in Survivors of Pediatric Brain Tumors | completed | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05427838 | Simulation Training in Emergency Department Imaging 2(STEDI2) | completed | N/A | 173 | Oxford University Hospitals NHS TrustOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05786144 | Vestibular Schwannoma Organoids | completed | — | 100 | Maastricht Radiation OncologyOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06057168 | Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas(GDX-44-016) | completed | Phase 3 | 138 | GuerbetINDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT06592092 | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors | completed | N/A | 3 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03262636 | Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)(TumorGlow(TM)) | completed | Phase 1 | 363 | University of PennsylvaniaOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT07350382 | Predicting Cognitive Dysfunction After Pediatric Posterior Fossa Tumor Surgery | completed | — | 600 | West China HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07342686 | Hypothalamic-Stratified Nursing Pathway for Pediatric Craniopharyngioma | completed | — | 500 | West China HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07342699 | Location-Molecular Integrated Outcomes in 450 Cerebellar Glioma Microsurgical Cases | completed | — | 450 | West China HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07343492 | fMRI Reveal Functional Preservation in Glioma Peritumoral Edema | completed | — | 44 | West China HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07339241 | Abdominal Circumference as a Predictor of Operative Time in Retroperitoneal Adrenalectomy for Pheochromocytoma | completed | — | 159 | Asan Medical CenterOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07321262 | Machine Learning to Predict Postoperative Pneumonia in Brain Tumor Patients(ML-PNEUMO-BT) | completed | — | 1,856 | Ming YangOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients(NESTLES) | completed | Phase 1 | 19 | Baylor College of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06031194 | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma | completed | — | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04113395 | Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium(CAMOMILLE) | completed | — | 514 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02617745 | Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid(GLIOPLAK) | completed | Phase 2 | 244 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07305285 | Roy Adaptation Model Improves Mood and QOL After Giant Acoustic Neuroma | completed | N/A | 160 | West China HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03406208 | Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing | completed | N/A | 228 | Massachusetts General HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05735171 | Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence(SupraGlio-AI) | completed | N/A | 20 | Hospital del Rio HortegaOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT02473380 | Fluorescence Spectroscopy Guided Surgery(GLIOSPECT) | completed | Phase 1 | 11 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | completed | Phase 2 | 24 | Peking Union Medical CollegeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT01850888 | MIBG for Refractory Neuroblastoma and Pheochromocytoma | completed | N/A | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04566185 | Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma(EVA DOPA) | completed | N/A | 14 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06451042 | FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)(FET-TREAT) | completed | — | 11 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2026source: clinicaltrials